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Intra-tumor heterogeneity (ITH) drives neoplastic progression and therapeutic resistance. We used 
EXPANDS and PyClone to detect clones >10% frequency within 1,165 exome sequences from 
TCGA tumors. 86% of tumors across 12 cancer types had at least two clones. ITH in nuclei 
morphology was associated with genetic ITH (Spearman ρ: 0.24–0.41, P<0.001). Mutation of a 
driver gene that typically appears in smaller clones was a survival risk factor (HR=2.15, 95% CI: 
1.71–2.69). The risk of mortality also increased when >2 clones coexisted (HR=1.49, 95% CI: 
1.20–1.87). In two independent datasets, copy number alterations affecting either <25% or >75% 
of a tumor’s genome predicted reduced risk (HR=0.15, 95% CI: 0.08–0.29). Mortality risk also 
declined when more than four clones coexisted in the sample, suggesting a tradeoff between costs 
and benefits of genomic instability. ITH and genomic instability have the potential to be useful 
measures universally applicable across cancers.
Cancers are a mosaic of clones of varying population sizes, different genetic makeup and 
distinct phenotypic characteristics1–4. This intra-tumor heterogeneity provides the fuel for 
the engine of natural selection that drives the process of carcinogenesis and acquired 
therapeutic resistance in neoplasms1,5. When analyzing genome sequencing data derived 
from single tumor samples, it is important to recognize that technically, sequences obtained 
from each tumor sample encode a tumor-metagenome, since they represent the aggregate 
genomes of all clones that coexist within the sample6,7,10–12. Recently, McGranahan et al. 
used exome-sequencing data derived from single tumor samples to determine the clonal 
status of known, actionable drivers across 9 cancer types and to identify events that trigger 
clonal expansions, causing ITH6. However, the availability of just one sample per tumor and 
moderate sequencing depth has limited the opportunity for systematic analysis of extent and 
the clinical consequences of ITH, in previous pan-cancer studies12–14,3,7–9. To overcome 
these limitations, a variety of different algorithms have been developed to deconvolute 
tumor-metagenomes. These algorithms estimate the cellular prevalence of mutations and 
quantify ITH15–19. We leveraged two of these tumor mixture separation algorithms, 
EXPANDS18 and PyClone17, to quantify ITH from TCGA exome sequencing data, and to 
validate the robustness of our results.
RESULTS
Intra-tumor genetic heterogeneity exists in all tumor types
We measured the number and size of genetically diverse clones of 1,165 primary tumor 
samples across 12 cancer types from The Cancer Genome Atlas (TCGA), using paired 
tumor-normal exome sequencing data. These samples originated from a single sequencing 
center (the Broad Institute) and were chosen because they fulfilled established strict criteria 
to obtain uniform sequence data quality and depth (Supplementary Fig. 1.1). As clone 
detection sensitivity is highly dependent on genomic depth and breadth of coverage, these 
criteria are necessary to ensure that measures of ITH derived from these sequences are 
comparable. Detailed inclusion criteria are available in Supplementary Note 1.2.
Somatic single nucleotide variants (SNVs) and copy number variants (CNVs) were called 
using MuTect20 and ExomeCNV21 respectively (Supplementary Fig. 1.3). We distinguished 
non-synonymous SNVs and splice site or regulatory region SNVs (generally referred to as 
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non-silent) from synonymous SNVs and SNVs within intergenic and intronic regions 
(referred to as silent). The incidence of CNVs and somatic non-silent SNVs varied 
considerably within and between tumor types (Fig. 1a–c), similar to results obtained from 
other genome wide sequencing studies13,22,23.
EXPANDS was applied to all detected somatic SNVs (including silent SNVs), loss of 
heterozygosity (LOH) and copy number estimates to infer the number, size, and genetic 
content of subpopulations of cells that coexisted in the tumor (Fig. 1d). Briefly, EXPANDS 
models the cellular prevalence of each SNV as a copy-number dependent probability 
distribution. Subsequently, these cellular prevalence distributions are clustered to obtain the 
genetic content of each subpopulation, i.e. the set of SNVs and CNVs that accumulated in 
ancestral cells prior to each clonal expansion. Previous results18 indicate that the sequencing 
data available per tumor (on average 5,221 Mb reads) translates to an accuracy of 50–80% at 
which EXPANDS detects genetic heterogeneity at a macroscopic resolution24 (i.e. clones 
present in ≥ 10% of the sample). An independent algorithm, PyClone17, was used to validate 
the conclusions derived from EXPANDS. PyClone infers the cellular prevalence of SNVs 
differently from EXPANDS. In particular, PyClone does not model subclonal CNVs and 
leverages high depth rather than high breadth of sequencing17 (Supplementary Note 2.1).
In general, the cellular prevalence of SNVs assigned by PyClone and EXPANDS was 
concordant for SNVs located within segments of clonal copy number (Spearman ρ=0.77). 
However, for regions in which CNVs affect only a subset of tumor cells, EXPANDS and 
PyClone tended to make different inferences for cellular prevalence of SNVs within those 
regions (ρ=0.25; Supplementary Fig. 2.1b,c).
Subpopulations detected within the same tumor sample may have sizes that cumulatively 
exceed 100%, as a subpopulation may be nested in a parental population that carries earlier 
mutations. Both algorithms detect such nested subpopulation compositions. We will refer to 
these inferred subpopulations as clones, and to the cellular prevalence of a subpopulation 
within the tumor sample as its clone size. As noted previously, we define the term ‘tumor-
metagenome’ as the aggregate genomes of all co-existent clones within a tumor.
Assuming a monoclonal tumor origin, the largest inferred clone in each sample corresponds 
to the first (founder) clonal expansion. This holds true, regardless of the fitness difference 
between the founder and descending clones. The cellular prevalence of founder-mutations 
will always be greater than or equal to the cellular prevalence of mutations acquired by 
descendant subclones, even if these later subclones proliferate faster than the founder. This 
implies that the size of the largest clone is also a measure of tumor purity (Fig. 1e); this was 
confirmed by an independent study that compared the performance of EXPANDS to four 
other methods that predict tumor purity25. The size of the largest clone was correlated to 
tumor purity as predicted from expression profiling with ESTIMATE26 (EXPANDS: 
Pearson r=0.43; P≪1E–6; PyClone: r=0.63; P≪1E–6; Supplementary Fig. 2.2a).
We observed that the number of somatic SNVs in large clones correlated with age at 
diagnosis (ρ=0.3; P≪1E–6), a result previously reported for chronic lymphocytic leukemia 
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(CLL)10. In addition, the number of SNVs in small clones also correlated with age (ρ=0.18; 
P=5E–6; Supplementary Fig. 2.2b,c).
We compared the extent of genetic ITH across and within tumor types (Fig. 2a–d). The 
difference between tumor types in the number of clones they harbor was similar before 
(Supplementary Fig. 2.3a) and after correcting for tumor purity (Fig. 2c, Online Methods). 
On average four clones were estimated to coexist in a tumor at the time of biopsy or surgical 
resection (median clone number EXPANDS: 5; PyClone: 3; Fig. 2a,b). There was a median 
of 10 (EXPANDS estimate) to 16 (PyClone estimate) non-silent somatic SNVs per clone 
and the distribution of clone sizes across tumor types was relatively uniform (Supplementary 
Fig. 2.4a and Fig. 2e–h). Notably, reduced detection sensitivity (due to low tumor purity) 
was not sufficient to explain the smaller number of clones observed in low-purity tumors 
(Supplementary Fig. 2.4b). In 14% (EXPANDS estimate) to 20% (PyClone estimate) of the 
analyzed tumor samples, only a single, genetically homogeneous cell population was 
detected. Even for thyroid carcinoma – the least heterogeneous tumor type – two or more 
clones were predicted to coexist in >50% of the samples (EXPANDS estimate: 52%; 
PyClone estimate: 65%). Therefore, we concluded that genetic ITH occurs in the vast 
majority of cancers represented among the 12 types that we included in this study.
Driver genes are mutated in clones of characteristic sizes
To investigate the influence of driver gene mutation incidence on genetic ITH, we analyzed 
259 cancer driver genes (CAN-genes; Supplementary Table 3.1). A gene was included as 
significantly associated with a given cancer type based on: i) prior experimental evidence; ii) 
frequency of gene-mutations in our sample cohort and iii) mutation deleteriousness (Online 
Methods). Shown in Fig. 3a are the 124 non-private CAN-genes (48%) that are mutated in a 
minimum of two cancer types.
Next, we tested whether clones differ in their size depending on which CAN-genes are 
mutated in the corresponding clones. The size of a clone depends on its selective fitness 
(how fast it expands relative to the other clones within a tumor) and on its formation time 
(when the underlying clonal expansion started). CAN-gene SNVs specific to a given clone 
may therefore have a direct impact on its size. To test this possibility, we first normalized 
clone sizes by tumor purity. We then calculated the mean and variance in clone-size among 
all clones with non-silent mutations in a given CAN-gene and compared them to the 
variance calculated from random samples of clone sizes from our data (Supplementary Fig. 
3.2).
The size of clones harboring CAN-gene mutations varied across CAN-genes (Fig. 3a) and 
was correlated to both, the relative order of driver gene mutations reported in earlier 
studies13,28–31 and to the clone sizes predicted by PyClone (0.43<r<0.94; 3.4E–18<P<0.12; 
Supplementary Fig. 3.3a,b). Across tumor samples, and even across tumor types, CAN-
genes were often mutated in clones of a characteristic size, i.e. the variance in clone size was 
significantly lower than expected by chance (one-sided t-test: P<0.05; Fig. 3a). Citing an 
example, TP53 SNVs were found in larger clones (EXPANDS: 0.811; PyClone: 0.746 
average cancer-cell fraction) in all nine cancers significantly associated with TP53 genetic 
aberrations. In contrast, somatic SNVs in DMBT1 were found in smaller clones 
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(EXPANDS: 0.641; PyClone: 0.652 average cancer cell fraction) in the three cancers in 
which DMBT1 was among the drivers (Fig. 3a).
For a subset of CAN-genes however, we found significant differences in the dominance of 
mutated clones depending on cancer type. For example, clones with ERBB3 mutations were 
larger in bladder cancer than they were in any other cancer type, while clones with PTEN 
mutations grew particularly large in Glioblastoma (Fig. 3b). Clones with SNVs in CAN-
genes that are druggable (n=98) did not have significantly different sizes as compared to 
clones with SNVs in the remaining CAN-genes (n=161; T-test: P=0.77).
Furthermore, clone size inferiority of a mutated CAN-gene (as shown in Fig. 3a) was 
correlated to the propensity of the CAN-gene as risk factor (univariate Cox EXPANDS: 
P=3.2E–07, HR=2.86; PyClone: P=0.005, HR=1.67). For instance, mutations in CAN-genes 
within the lower 5% average clone size were associated with poor outcome (Fig. 3c). This 
relation was also significant in low-grade gliomas, kidney carcinoma and glioblastoma 
(Supplementary Table. 4.3a). Several cellular functions/pathways were associated 
exclusively with small-size and medium-size clones, but not with large-size clones including 
tyrosine-protein kinase activity (P=1.39E–12) and positive regulation of locomotion 
(P=3.39E–9) (Supplementary Tables 3.1 and 3.4).
Next, we used the size-rankings of clones with CAN-gene mutations to compare cancer 
types (Fig. 3d). For CAN-genes that are critical among different tumor types, we measured 
whether clones containing mutations in these genes are of similar size, regardless of tumor 
type. Head and neck cancer, low-grade glioma and glioblastoma showed significant clone-
size similarities to most other cancer types (0.12≤ρ≤0.43; P<0.05), though all cancers were 
similar to at least one other cancer type (Fig. 3d; PyClone and EXPANDS: 0.12≤ρ≤0.58; 
P≤0.05).
Finally, we tested whether distinct SNV categories differ in how well they model the number 
of detected clones per tumor. Per cancer type, silent SNVs in non-CAN-genes accounted for 
an average of 25% of the variability in the number of clones. Including silent SNVs in CAN-
genes as predictors of clone number did not improve the model. In contrast, including non-
silent SNVs in CAN-genes improved the predictions, accounting for 30% of the variability 
in the number of clones (log-likelihood test: P<0.05; Fig. 3e). These results suggest that 
mutations driving clonal expansions are more common among non-silent SNVs in CAN-
genes, than among other SNV categories (Online Methods and Supplementary Note 2.1).
Histologic ITH and proliferation rate reflect genetic ITH
Nuclear size and staining variability is a standard histomorphologic metric of tumor 
differentiation, facilitating comparisons across cancers independent of tissue origin. A total 
of 2,231 H&E images were available at TCGA for 930 (80%) of the analyzed tumor samples 
(Supplementary Fig. 1.3). To quantify histologic ITH from these images, we measured the 
variability in nuclei size and staining intensity (Supplementary Note 2.5). For each tumor, 
the established image-analysis software CellProfiler34 was used to measure the size and 
staining intensity of every nucleus detected on the tumor’s H&E images35,36. A 
histopathologist conducted an independent and blinded scoring of a subset of 17 H&E 
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images (Supplementary Fig. 2.6), which confirmed the accuracy of nuclear diversity scoring 
by CellProfiler (ρ=0.64, P=0.007; Fig. 4a,b).
The extent of nuclear ITH varied between tumor types (Fig. 4c). Greater nuclear diversity 
was observed with increasing clone number (Fig. 4d) in kidney cancer (ρ=0.413; FDR 
adjusted P=0.004), stomach cancer (ρ=0.406; FDR adjusted P=2.97E–4), head and neck 
cancer (ρ=0.278; FDR adjusted P=0.009), bladder cancer (ρ=0.246; FDR adjusted P=0.022) 
as well as across all 12 cancer types (ρ=0.243; FDR adjusted P=8.15E–13). Increased 
nuclear diversity with increasing clone number was observed for both PyClone and 
EXPANDS based clone number predictions, as well as after normalizing nuclear and genetic 
ITH measures to account for tumor purity (Supplementary Table 3.5).
We used mRNA expression levels of the proliferation marker KI67, available for 854 (73%) 
of the samples, to measure proliferation rate37. Clone number was significantly correlated to 
proliferation rate within low-grade glioma (ρ=0.18; P=0.021) and prostate cancer (ρ=0.21; 
P=0.046) as well as across cancers (ρ=0.31; P=2.69E–20). However, tumor-type specific p-
values did not remain significant after FDR correction for multiple testing (P>0.05). For a 
subset of cancer types (the three squamous cell carcinomas of the head and neck, lung and 
cervix), very heterogeneous tumors (>8 clones) had low KI67 expression (Supplementary 
Figure 2.7).
Overall, these results show that nuclear and cellular features typically associated with 
aggressive disease correlate with greater genetic ITH across cancer types.
Prognostic value of genomic instability and genetic ITH
We tested whether measures of genomic instability and genetic ITH (Supplementary Table 
4.1) could predict overall and progression free survival. We constructed univariate Cox 
models for each cancer type separately as well as pan-cancer Cox models (Supplementary 
Tables 4.2 and 4.3). Prostate adenocarcinoma and thyroid carcinoma were excluded from the 
cancer type specific survival analysis due to insufficient availability of uncensored survival 
information (Supplementary Table 1.4).
When considering each cancer type separately, no significant monotonic association 
between clone number and survival was evident (P>0.05; Supplementary Table 4.3), apart 
from gliomas (EXPANDS: P=0.03, HR=3.25; PyClone: P=0.04, HR=2.34). Across cancer 
types, the presence of more than two clones was associated with worse overall survival as 
compared to tumors in which either one or two clones were detected (Log-rank test 
EXPANDS: P=8.6E–4, HR=1.49; PyClone: P=0.09, HR=1.21; Fig. 5a and Supplementary 
Figs. 4.4a,d).
The association between clone number and survival was non-linear. An increased risk with 
increasing clone number was only observed for up to 4 clones. Additional diversification, 
beyond 4 clones, did not impart further risk. In fact, a tendency for reduced risk was 
observed among highly diverse tumors. This risk reduction did not reach significance in the 
univariate setting (Supplementary Fig. 4.5a), although it was significant in the multivariate 
analysis described below. The non-linear relationship between ITH and survival was also 
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apparent when using alternative measures of ITH (e.g. nuclear diversity or accounting for 
differential tumor purity; Supplementary Fig. 4.5b,d,e).
A measurement of genomic instability is the fraction of the tumor-metagenome affected by 
CNVs (CNV abundance)38. Because genomic instability correlates with ITH 
(Supplementary Fig. 4.5f), we hypothesized that increased genomic instability necessary to 
produce a high level of ITH (i.e. >4 detected clones) may adversely affect tumor cell fitness 
following the generation of deleterious CNVs. We therefore analyzed the impact of somatic 
CNV abundance in the tumor-metagenomes and its relation to ITH. We find that low or high 
CNV abundance, i.e. CNVs affecting either a very low or a very high fraction of the tumor-
metagenome, was predictive of improved survival (Log-rank test: P=5E–6; HR=0.15; Fig. 
5b). This was not the case for low/high somatic SNV abundance (adjusted P>0.05; 
Supplementary Table 4.2a,b). We validated this result using CNVs measured by genome-
wide SNP-arrays from: i) the same tumor samples and ii) an independent dataset consisting 
of 2,010 tumor samples, across seven distinct cancer types. Both validation analyses 
confirmed that intermediate CNV abundance is associated with poor survival 
(Supplementary Table 4.6 and Fig. 4.7a,b).
The highest risk was observed among individuals with 50–75% of their tumor-metagenome 
affected by CNVs in both the original and the independent datasets (Fig. 5c and 
Supplementary Figs. 4.7a,b). In fact, tumors with 50–75% CNV abundance did represent the 
highest risk group among individuals with bladder cancer, head and neck cancer, lung 
adenocarcinoma, stomach adenocarcinoma, cervical cancer and low-grade gliomas 
(Supplementary Fig. 4.8). These observations suggest the existence of an optimal degree of 
genomic instability that is independent of tumor-type.
Of the 12 tumor types, Glioblastoma was the only cancer for which >75% CNV abundance 
was associated with the worst prognosis (Supplementary Fig. 4.8g). Notably, with 85% of 
individuals diagnosed with Glioblastoma undergoing chemo- and/or radiotherapy, DNA 
damaging therapy is administered more frequently for Glioblastoma than for any of the other 
analyzed tumor types (Supplementary Table 1.4). Therefore we verified whether or not 
adjuvant chemo- or radiotherapy affected the non-linear association between CNV 
abundance and survival. In contrast to the 643 individuals who did not undergo chemo- or 
radiotherapy, the association between intermediate CNV abundance and poor survival was 
not significant amongst the 514 individuals treated with DNA-damaging agents (Fig. 5d). 
This finding was confirmed in the independent SNP-array dataset, where tumors with 
intermediate CNV abundance did represent the highest risk group among untreated, but not 
among individuals treated with chemo- or radiotherapy (Supplementary Fig. 4.7c,d).
A tumor with a critical level of >75% CNV abundance per tumor-metagenome may either be 
composed of many clones with low CNV abundance per clone, or few clones, each carrying 
high CNV abundance (Supplementary Fig. 4.9b,c). We used a clone number of 2 and 75% 
CNV abundance as thresholds to stratify untreated individuals into four groups with: i) CNV 
abundance below 75% and maximum 2 clones; ii) CNV abundance below 75% and 
minimum 3 clones; iii) CNV abundance above 75% and maximum 2 clones; and iv) CNV 
abundance above 75% and minimum 3 clones. Overall survival between these four groups 
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was significantly different (Log- rank test EXPANDS: P=0.0015; HR=1.4). In general, as 
before, low clone number was associated with good outcome. In particular, the best outcome 
among the four groups was observed when a high CNV burden was shared among ≤2 clones 
(group iii; Fig. 5e and Supplementary Fig. 4.4e). When stratifying individuals who had 
undergone chemo- and/or radiotherapy in the same way, differences in clone number, rather 
than CNV burden, were associated with differences in overall survival between the four 
groups (Log-rank test EXPANDS: P=0.038; HR=1.4; Fig. 5e). Stratification based on 
PyClone derived clone numbers also supported these conclusions, albeit with borderline 
significance (P≤0.07, Supplementary Fig. 4.4b,c).
To account for factors that may confound the associations observed between clinical 
outcome and genetic ITH, the prognostic significance of clone number and low/high CNV 
abundance were evaluated with multivariate Cox models (Online Methods). All tumor types 
were included in a pan-cancer Cox model, except for gliomas, as the staging system is not 
applicable to gliomas. Across cancers, both, genomic instability and genetic ITH remained 
significantly associated to survival in the multivariate setting (Table 1). As concluded from 
univariate analysis (Supplementary Fig. 4.5a,b), the relation between clone number and 
survival was non-linear: an increased risk with increasing clone number was only observed 
for up to 4 clones. Additional diversity beyond 4 clones, was associated with an increase in 
overall CNV burden and a significant decrease in risk of mortality (Supplementary Fig. 
4.5c,f). A similar scenario was observed within 8 out of the 10 analyzed cancer types, where 
the highest hazard was associated with an intermediate number of clones (between 3 and 5). 
ITH levels above/below an intermediate number of clones were associated with significantly 
reduced risk (multivariate Cox: HR=0.01–0.21; P≤0.05) relative to the intermediate group in 
head and neck cancer, melanoma and kidney cancer (Supplementary Fig. 4.5g and Table 
4.10).
DISCUSSION
Quantification of ITH is a key measure of tumor evolution. We performed a cross-sectional 
analysis of ITH in 1,165 cancers from 12 cancer types, revealing the extent of ITH, and 
supporting its potential as a universal, though perhaps non-linear, prognostic biomarker. 
Evidence from two tumor mixture separation algorithms and from H&E imaging analysis, 
collectively indicate that ITH is a feature of the vast majority of cancers diagnosed.
To our knowledge, this is the first report of a cross-cancer correlation between genetic ITH 
and histopathologic ITH, suggesting that measures of tumor H&E sections can provide a 
proxy for genetic ITH. Currently, single tumor samples provide the only opportunity to 
study genetic ITH in a large pan-cancer cohort6. Measuring ITH from single tumor samples 
benefits from high depth and high genomic breadth of coverage. Exome-sequencing data 
represents the best tradeoff between these two sequencing- design parameters that is 
currently available at TCGA, across a broad range of tumors and cancer types. Using 
exome-sequencing to quantify ITH implies that clone distinction is confined to coding 
regions. Two clones that only differ in non-coding regions would be indistinguishable. 
Whole genomes sequenced at higher depth and multiple geographical tumor-samples will 
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further improve our sensitivity to detect small clones and increase our resolution on clonal 
composition and its variability across cancer types.
Our results show that mutations in particular driver genes are associated with clones of a 
characteristic size, often independent of tumor type. This observation suggests that there 
appear to be constraints on the order in which neoplastic cells acquire driver events43 or that 
these events differ in the magnitude of the fitness-advantages they provide to neoplastic cells 
(Fig. 3a). Small clones may be fit, but evolve late in tumor progression. Alternatively, they 
may be less fit, but function as a “cornucopia of evolution” from which new clones 
frequently emerge. Both alternatives explain both, why these clones are so small and why 
their presence is associated with poor outcome (Fig. 3c). Importantly, the number of mutated 
CAN-genes did not predict outcome, suggesting that the relation between survival and 
presence of small clones was not confounded by CAN-gene mutation incidence.
The significant association between high clone number and poor survival detected in the 
combined analysis of low-grade glioma and glioblastoma may be interesting in the context 
of the highly variable clinical behavior of low-grade gliomas. A recent study found that 
histopathologic classification may overlook a subset of glioblastoma tumors, labeling them 
as low-grade gliomas7. Knowing the extent of ITH may help improve differential diagnosis 
between glioblastoma and low-grade glioma44.
As previously observed in ovarian, gastric, non-small cell lung cancers and ER− breast 
cancers45,46, individuals with intermediate CNV burdens detected in their primary untreated 
tumor had the worst overall survival. We find this association is present across several tumor 
types, but its strength varies with the type of therapy the individuals received subsequently. 
Our results suggest a potential advantage when tumors with intermediate levels of CNVs are 
treated with adjuvant chemo- and radiotherapy (Fig. 5d). Chemo- and radiotherapy may be 
particularly effective against tumors with intermediate CNV burdens, by pushing them past 
the limit of ‘tolerable’ genomic instability. Our results from two distinct high-throughput 
technologies measuring CNV abundance in two independent pan-cancer cohorts suggest that 
this limit is exceeded when >75% of a tumor’s metagenome is affected by CNVs, 
independent of cancer type. Given that >37% of cancers have been shown to undergo whole 
genome doubling events12, in will be of interest to see whether these tumors have the same 
phenotype as tumors with >75% CNV burden.
In light of recent evidence supporting a stronger role of CNVs than SNVs in developing and 
maintaining ITH11, this upper limit of tolerable genomic instability may be responsible for 
the non-linear association we observed between genetic ITH and survival. Previously, low 
ITH has been found to predict favorable prognosis in Barrett’s esophagus49,50, head and 
neck cancer11, as well as leukemia10,51. Consistent with these studies we found that the 
presence of only one or two clones is in general prognostic of favorable outcome, especially 
when these few clones share a high CNV burden. However, diversification beyond four 
clones was associated with decreased risk.
The decrease in risk may be because large numbers of clones can attract more immune-cells. 
Alternatively, the decrease in risk may be in part due to the technical difficulty of 
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distinguishing between ITH and genomic instability, in particular as both measures increase. 
Finally, it may be a consequence of a tradeoff that exists between the chance of acquiring an 
advantageous alteration initiating a new clonal expansion and the risk of generating inviable 
daughter cells. The observed synchronous increase of ITH and CNV burden suggests that 
efforts aimed at modulating this tradeoff may represent a new therapeutic avenue to slow 
tumor evolution and improve clinical outcomes.
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Figure 1. Tumor-metagenomes and subclonal genomes in 12 tumor types from TCGA
(a) Prevalence of non-silent somatic SNVs per tumor. Percentage of tumor-metagenome 
affected by (b) single copy gains/amplifications and (c) single copy losses. (d) Clonal 
composition inferred from SNVs and copy numbers. Every sample contains a founder tumor 
population (yellow), identified as the largest clone within the sample. Each change in color 
marks the presence of an additional clone at the indicated size, calculated as % of the 
founder population size (y-axis). Color-variety within each tumor-type panel reflects the 
extent of intra-tumor heterogeneity in the corresponding tumor type. The average number of 
detectable (>10% frequency) clones increases from thyroid carcinoma (left) to melanoma 
(right). (e) The size of the founder clone is a measure of tumor purity. The exact number of 
tumors of each type (n) is indicated at the bottom of each panel.
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Figure 2. Intra-tumor genetic heterogeneity in 12 tumor types
Clone number distribution predicted by EXPANDS (a) and PyClone (b) across tumor types. 
Violin plots of clone number distribution predicted by EXPANDS (c) and PyClone (d) 
within tumor types. Clone size distribution predicted by EXPANDS (e) and PyClone (f) 
across tumor types. Violin plots of clone size distribution predicted by EXPANDS (g) and 
PyClone (h) within tumor types. EXPANDS derived clone numbers (a, c) and all clone sizes 
(e-h) have been normalized by tumor purity. For PyClone derived clone numbers, 
normalization by tumor purity was not necessary. Violin plots contain marks for the mean 
(black lines) and median (red lines). [Thyroid = Thyroid Carcinoma; Prostate = Prostate 
Adenocarcinoma; Kidney = Kidney Renal Clear Cell Carcinoma; Head and Neck = Head 
and Neck Squamous Cell Carcinoma; Cervical = Cervical Squamous Cell Carcinoma and 
Endocervical Adenocarcinoma; Stomach = Stomach Adenocarcinoma; Lung (adeno) = Lung 
Adenocarcinoma; Bladder = Bladder Urothelial Carcinoma; Lung (squam) = Lung 
Squamous Cell Carcinoma; Melanoma = Skin Cutaneous Melanoma].
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Figure 3. Association of driver gene mutations to clone size and clone number
(a) Clone sizes were predicted by EXPANDS for mutations in 124 CAN-genes and 
normalized by purity. For each cancer type CAN (x-axis) and gene G (y-axis), average clone 
size was calculated across all CAN clones that harbor non-silent SNVs in G. Blank entries 
denote that G was not significantly associated to CAN. SNVs in CAN-genes often have the 
tendency to occur in clones of characteristic sizes, independent of cancer type (one-sided t-
test: *P<0.05). (b) Mutations in some CAN-genes tend to drive large clonal expansions in 
certain cancer types, for example ERBB3 mutations in bladder carinoma and PTEN 
mutations in Glioblastoma (one-sided t-test: **P<1E–4). (c) SNVs in CAN-genes that 
characteristically grew to smaller clones predicts poor prognosis across tumor types (Log-
rank test: P=2.9E–4; HR=2.72). (d) Clones with CAN-gene mutations have similar sizes 
across certain tumor types, suggesting the order/selective advantage of CAN-gene mutations 
is often not tissue-specific. Pairwise similarity between tumor types is calculated as 
Spearman correlation (**P<0.01; *P<0.05) based on EXPANDS (above diagonal) and 
PyClone results (below diagonal). (e) The number of clones identified in a sample depends 
on SNV incidence, but not all SNV categories are equally associated with the resulting 
number of clones. Non-silent SNV incidence in CAN-genes (red; mean = 2 genes) explain 
variability in clone number better than silent SNV incidence in CAN-genes (yellow; mean = 
1 gene) or non-silent SNV incidence in non-CAN-genes (cyan; mean =128 genes). Log-
likelihood test: **P<0.01; *P<0.05.
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Figure 4. Intra-tumor nuclear diversity accompanies intra-tumor genetic diversity
(a) Quantitation of intra-tumoral nuclear diversity from H&E images. Conventional H&E 
stainings (upper panels) of two bladder cancer specimens are shown. The lesion on the left 
(TCGA-GD- A3SO) demonstrates monomorphic high-grade nuclei with open chromatin and 
prominent nucleoli, while the lesion on the right (TCGA-BT-A0YX) demonstrates nuclei 
that vary from small with condensed chromatin to very large with open chromatin 
(anisochromasia). CellProfiler outlines nuclei (lower panels) and quantifies nuclear 
variability from the H&E images. (b) Quantitation of nuclear diversity is shown for the two 
bladder cancer specimens in panel a (black arrows) along with 15 other bladder cancer 
specimens. Independent ranking of intra-tumor nuclear diversity across these 17 bladder 
cancer specimens by an expert histopathologist (blue) validates the automated nuclear 
diversity measures (red) (ρ=0.64; P=0.007). (c) Violin plots of nuclear diversity within 
tumor types. Nuclear diversity was normalized to account for differences in tumor purity. 
Tumor types are ordered according to their extent of genetic ITH (Fig. 2b). (d) Nuclear 
diversity per tumor (x-axis; quantified based on nuclear intensity and size diversity) 
increases with increasing clone number per tumor (y-axis). This is true for all cancers 
combined (ρ=0.243; P=6.30E–14) as well as for the specific types shown (* ρ>0.25; P<0.01; 
** ρ>0.4; P<0.001). The p-values shown here have not been corrected for multiple 
hypothesis testing.
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Figure 5. Clone number and CNV burden appear to be universal prognostic biomarkers
(a) The presence of more than two clones detected by EXPANDS in a tumor sample predicts 
poor overall survival across all 12 tumor types (HR=1.497). (b) Survival curves are stratified 
by the fraction of the tumor-metagenome affected by CNVs (CNV abundance) across 12 
tumor types. Intermediate levels of CNV abundance predict poor outcome (HR=0.597). (c) 
Hazard ratios as a function of CNV abundance. The hazard ratio for each of the upper three 
CNV abundance quartiles is calculated relative to the hazard of individuals in the lowest 
quartile (0–25% CNV abundance) and displayed along with 95% confidence interval. (d) 
Individuals treated with chemo- or radiotherapy (right panel) and untreated individuals (left 
panel) are stratified by CNV abundance. Individuals with low (<25%) or high CNV 
abundance (>75%) progress more slowly than individuals with intermediate CNV abundance 
levels (25–75%), especially within the group that did not receive adjuvant chemo- or 
radiotherapy. (e) Untreated individuals (left panel) with few clones in their tumors (blue 
lines) survive longer than untreated individuals with a large number of clones detected in 
their tumors (red lines), especially when these few clones share a large CNV burden (blue 
continuous line). This is not the case for treated individuals (right panel). All hazard ratios 
were calculated with log-rank tests (** P<0.005; * P<0.05; • P<0.1). For each stratum in 
panels (a,b,e) at least 50% of the 12 analyzed tumor types were represented at >5% 
frequency.
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Table 1
Pan-cancer multivariate Cox model of overall survival.
P-value Hazard ratio Standard error (Coefficient) Z-score
4 clones (Ref.) NA 1.000 NA NA
1 or 2 clones vs. Ref. 0.006 0.442 0.300 −2.723
3 clones vs. Ref. 0.076 0.618 0.271 −1.776
5 clones vs. Ref. 0.007 0.450 0.296 −2.703
6 or 7 clones vs. Ref. 0.014 0.503 0.279 −2.463
8 or 9 clones vs. Ref. 0.014 0.489 0.290 −2.469
10 or more clones vs. Ref. 0.003 0.389 0.314 −3.011
Age at diagnosis 0.002 5.938* 0.579 3.078
Low/high CNV abundance 1.81E–04 0.129 0.548 −3.744
Pathologic stage 2.90E–08 3.339 0.217 5.548
MKI67 mRNA expression 2.21E–04 5.236 0.448 3.694
% Lymphocytes 0.141 0.310 0.796 −1.473
Model summary Likelihood ratio test=92 on 11 degrees of freedom, P=6.88E–15, n= 610, number of events= 157
*
The hazard ratio for ‘age at diagnosis’ may not be reliable (Test of Proportional Hazards: P=0.007).
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